Orbimed Advisors Llc - Jan 30, 2024 Form 4 Insider Report for ArriVent Biopharma, Inc. (AVBP)

Role
Director, 10%+ Owner
Signature
OrbiMed Advisors LLC By: /s/ Douglas Coon, Chief Compliance Officer
Stock symbol
AVBP
Transactions as of
Jan 30, 2024
Transactions value $
$7,999,992
Form type
4
Date filed
1/31/2024, 04:12 PM
Previous filing
Jan 26, 2024
Next filing
Feb 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVBP Common Stock Conversion of derivative security +822K 822K Jan 30, 2024 See footnotes F1, F2, F4
transaction AVBP Common Stock Conversion of derivative security +822K 822K Jan 30, 2024 See footnotes F1, F3, F4
transaction AVBP Common Stock Conversion of derivative security +470K +57.14% 1.29M Jan 30, 2024 See footnotes F1, F2, F4
transaction AVBP Common Stock Conversion of derivative security +470K +57.14% 1.29M Jan 30, 2024 See footnotes F1, F3, F4
transaction AVBP Common Stock Purchase $4M +222K +17.21% $18.00* 1.51M Jan 30, 2024 See footnotes F2, F4, F5
transaction AVBP Common Stock Purchase $4M +222K +17.21% $18.00* 1.51M Jan 30, 2024 See footnotes F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVBP Series A Preferred Stock Conversion of derivative security -822K -100% 0 Jan 30, 2024 Common Stock 822K See footnotes F1, F2, F4, F6
transaction AVBP Series A Preferred Stock Conversion of derivative security -822K -100% 0 Jan 30, 2024 Common Stock 822K See footnotes F1, F3, F4, F6
transaction AVBP Series B Preferred Stock Conversion of derivative security -470K -100% 0 Jan 30, 2024 Common Stock 470K See footnotes F1, F2, F4, F6
transaction AVBP Series B Preferred Stock Conversion of derivative security -470K -100% 0 Jan 30, 2024 Common Stock 470K See footnotes F1, F3, F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis.
F2 These securities are held of record by OrbiMed Asia Partners IV, L.P. ("OAP IV"). OrbiMed Asia GP IV, L.P. ("Asia GP IV") is the general partner of OAP IV and OrbiMed Advisors IV Limited ("Advisors IV") is the general partner of Asia GP IV. OrbiMed Advisors LLC ("OrbiMed Advisors") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV.
F3 These securities are held of record by OrbiMed Private Investments VIII, L.P. ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
F4 This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
F5 Reflects shares purchased in the Issuer's initial public offering.
F6 The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering.